Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS

CVS HEALTH CORPORATION (CVS)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

CVS Health : U.S. judge concerned over government nod for CVS-Aetna deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/04/2018 | 09:16pm CET
FILE PHOTO: The CVS logo is seen at one of their stores in Manhattan, New York, U.S.

WASHINGTON (Reuters) - A federal judge who has been asked to sign off on the U.S. government's decision to approve CVS Health Corp's acquisition of insurer Aetna Inc said Tuesday he was "less convinced" than the government that the companies had struck a deal that ensured the merger was legal under antitrust law.

Judge Richard Leon of the U.S. District Court for the District of Columbia had complained last week in a hearing that the two sides had treated him as a "rubber stamp" for the agreement. CVS closed the $69 billion transaction last week and began the integration process.

"At this stage, I am less convinced of the sufficiency of the government's negotiated remedy than the government is," he wrote in the order issued on Tuesday.

The Justice Department approved the merger of CVS, a pharmacy chain and benefits manager, and Aetna on condition that the health insurer sell its Medicare Part D drug plan business to WellCare Health Plans Inc. That sale was completed last month.

Also in the order, Leon asked the government and the companies to file a brief by Dec. 14 to show why their integration should not be halted while he considers whether or not to approve the consent decree reached in October.

Most consent agreements that the antitrust agencies strike with companies to resolve competitive concerns are approved by federal courts with little fuss under the 1974 Tunney Act, which requires courts to ensure the agreements are in the public interest.

Companies generally do not wait for final court approval before closing their transactions.

(Reporting by Diane Bartz; Editing by Bernadette Baum)

Stocks mentioned in the article
ChangeLast1st jan.
CVS HEALTH CORPORATION -1.52% 73.37 Delayed Quote.2.76%
WELLCARE HEALTH PLANS -0.18% 244.35 Delayed Quote.21.50%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORPORATION
09:34aCVS HEALTH : Sharecare launches Sharecare Rx to help make medications more affor..
AQ
12/13CVS and Delta fall while Aflac and General Electric jump
AQ
12/12CVS HEALTH : Public and Private Organizations Convene to Improve Health of Hispa..
PR
12/11CVS HEALTH : Statement on PA Auditor General’s Report on PBMs
PU
12/07CVS HEALTH : Walgreens debuts expanded home delivery service
AQ
12/06CVS HEALTH : Walgreens expands prescription delivery program nationwide
AQ
12/05CVS HEALTH : Introduces New Approach to Pricing of Pharmacy Benefit Management S..
PR
12/04CVS HEALTH : U.S. judge concerned over government nod for CVS-Aetna deal
RE
12/04CVS PHARMACY : Completes Rollout of Time Delay Safes in All Kentucky Pharmacy Lo..
PR
12/04GLOBAL MARKETS LIVE : Elastic, Auto, CVS, Uniper…
More news
Financials ($)
Sales 2018 193 B
EBIT 2018 10 388 M
Net income 2018 1 927 M
Debt 2018 67 418 M
Yield 2018 2,74%
P/E ratio 2018 39,66
P/E ratio 2019 11,26
EV / Sales 2018 0,84x
EV / Sales 2019 0,63x
Capitalization 94 882 M
Chart CVS HEALTH CORPORATION
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 93,2 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
Eva C. Boratto Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors